Company Update and Introduction

November 22, 2013

Panna SharmaPresident and

Chief Executive Officer

Cancer Genetics, Inc.

8:30-9:00 am Breakfast

9:00-10:30 am Presentations

> Panna Sharma: Welcome, The NGS Marketplace:

Challenges, Opportunities & Launching OncoSpire

> Dr. Chaganti: CGI’s Contribution, The Project

Review Process & The Scientific Review

Committee at OncoSpire

> Dr. Farrugia: Center for Individualized Medicine

(Mayo) & Mayo’s NGS Contributions &

Infrastructure

> Dr. Chaganti & Dr. Farrugia: Our Three Initial

NGS Panels/ Projects, The Development Process

> Panna Sharma: Market Context & Wrapup

10:30-11:00 am Q&A and Open Dialogue

Agenda and

Presenters

RSK Chaganti, PhDFounder and

Member of the Board

Cancer Genetics, Inc.

Gianrico Farrugia, MDDirector, Center for

Individualized Medicine

Mayo Clinic

• $1 M funded in 2013 to initiate Joint Venture

• Upto $5 M in additional funding based on project milestones

• Projects Have 12 to 30 month development horizon

• Core operations based in Rochester, MN and leverage Mayo facilities

• World class NGS facility

• Best in class bioinformatics

• Globally leading clinicians

• Immediately integrated into care

• Scientific leadership

• Disease focus and stewardship

• Commercial focus and management

• Capital access and investment

Source: Research and Markets: Next Generation Sequencing.

Clinical adoption is early, but accelerating…there is

a “rush” to establish and validate meaningful

content that will drive usage and change patient

outcomes

$1.1 bil. NGS

Market (2012)

$2.7 bil. NGS

Market (2017)

Exponential growth in NGS publications

14 20 33 20 38 96261

515

990

1637

2590

0

500

1000

1500

2000

2500

3000

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Number of NGS Publications

CG

I e

sti

ma

te

Based on a PubMed search, with search term “next-generation sequencing” or “NGS”

Ten years ago there were 14 NGS publications…

for 2013 it is estimated to be 2,590

• Lack a patient informed

approach, they are driven

largely by large scale

gene and literature surveys

of known or actionable

sites

• Are not specific to

oncology sub-types

• Not unique and can be

readily replicated

• Are not answering new

questions about the

diseases

Current Approaches… Our Efforts & Approach

NGS Will Evolve…From Large Scale Gene Surveying To

Informed Discovery

• Emerge from clinically informed

teams that are trying to solve

unmet and critical needs

through genetic insight

• Disease-specific, multi-

disciplinary teams that can not

be readily recreated

• Involves novel discovery and

unique algorithms and/or

bioinformatics; potentially

patentable

• Asking questions about cancer

that are unmet and challenging

Solicited clinically-informed projects with cross-functional

team support from across Mayo

► Over 4,100 Staff Physicians & Scientist

► Over 1,200,000 Patients Annually

► Across Three US Locations: Rochester, Jacksonville, Scottsdale

20+ Projects

14 Projects

6 Projects

3 Projects

World-Class

Scientific

Review

Committee

RSK Chaganti, Ph.D.

Memorial Sloan-Kettering

Snee Chair of Cell Biology Program

Cancer Genetics, Inc.

Founder & Chairman CGI

Andrea Califano, Ph.D.

Columbia University

Director, JP Sulzberger Columbia Genome Center

Associate Director, Herbert Irving Comprehensive Cancer Center

Timothy A Chan, M.D., Ph.D.

Memorial Sloan-Kettering

Associate Professor

Human Oncology and Pathogenesis Program

Raj Dahiya, Ph.D.

Univ. of California, San Francisco

Professor, Department of Urology

Associate Editor, Cancer Research

Gianrico Farrugia, M.D.

Mayo Clinic

Director, Center for Individualized Medicine

Professor of Medicine, Physiology and Biomedical Engineering

Stephen J Russell, M.D., Ph.D.

Mayo Clinic

Director, Molecular Medicine

Professor of Medicine

Curtis A Hanson, M.D.

Mayo Clinic

Laboratory Director of Cytogenetics

Previous Medical Director of Mayo Medical Laboratories

Projects in development have significant clinical value and may yield

multiple focused panels that become the standard of care in NGS based oncology management.

Informed Discovery

Multiple Myeloma

Commercial Validation

Clinical Development

Market Entry(with partners)

Lung

Cancer

Follicular Lymphoma

1.6 millionnew cases

200,000new cases

20,920new cases